Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NTRBW
Upturn stock ratingUpturn stock rating

Nutriband Inc. Warrant (NTRBW)

Upturn stock ratingUpturn stock rating
$1.6
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: NTRBW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$1.6
high$

Analysis of Past Performance

Type Stock
Historic Profit -73.27%
Avg. Invested days 51
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.2
52 Weeks Range 0.75 - 5.25
Updated Date 06/10/2025
52 Weeks Range 0.75 - 5.25
Updated Date 06/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.5

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -211.78%

Management Effectiveness

Return on Assets (TTM) -36.45%
Return on Equity (TTM) -108.02%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 4420276
Shares Outstanding -
Shares Floating 4420276
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Nutriband Inc. Warrant

stock logo

Company Overview

overview logo History and Background

Nutriband Inc. focuses on transdermal drug delivery technology. While specific founding year and detailed milestones related solely to the *warrant* are not readily available, Nutriband's history is centered around developing abuse-deterrent transdermal patches.

business area logo Core Business Areas

  • Abuse-Deterrent Transdermal Technology: Development and commercialization of abuse-deterrent transdermal patches, primarily focusing on controlled substances.

leadership logo Leadership and Structure

Details on the warrant's leadership are not applicable; this relates to Nutriband Inc.'s management team. The structure is related to the terms of the warrant itself (exercise price, expiration date, etc.)

Top Products and Market Share

overview logo Key Offerings

  • Abuse-Deterrent Transdermal Patches: Nutriband's primary focus is on transdermal patches designed to deter abuse. Specific market share data is difficult to ascertain due to the niche nature of the market. Competitors include companies developing similar abuse-deterrent technologies, such as Collegium Pharmaceutical.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is constantly evolving, particularly in the areas of pain management and abuse-deterrent formulations. Increasing regulatory pressure and public health concerns drive innovation in this space.

Positioning

Nutriband positions itself as a leader in abuse-deterrent transdermal technology, aiming to provide safer alternatives to traditional pain medications.

Total Addressable Market (TAM)

The TAM for abuse-deterrent opioid formulations is substantial, estimated to be billions of dollars. Nutriband's positioning depends on the regulatory approval and market adoption of its products.

Upturn SWOT Analysis

Strengths

  • Proprietary abuse-deterrent technology
  • Focus on a growing market need
  • Potential for regulatory approval and market exclusivity

Weaknesses

  • Limited commercialized products
  • Reliance on regulatory approvals
  • Competition from larger pharmaceutical companies

Opportunities

  • Partnerships with pharmaceutical companies
  • Expansion into new therapeutic areas
  • Increased regulatory support for abuse-deterrent formulations

Threats

  • Failure to obtain regulatory approvals
  • Competition from alternative pain management therapies
  • Changes in regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • COLL

Competitive Landscape

Nutriband's advantage lies in its transdermal abuse-deterrent technology, but it faces competition from larger, more established pharmaceutical companies.

Growth Trajectory and Initiatives

Historical Growth: Growth depends on Nutriband Inc.'s progress and is speculative for a warrant

Future Projections: Future warrant performance is dependent on underlying stock performance and analyst estimates for Nutriband Inc.

Recent Initiatives: Recent Initiatives of Nutriband include its focus on its Aversa patch for pain management and deterring abuse.

Summary

Nutriband is a company specializing in abuse-deterrent transdermal technology, targeting the pain management market. Their success depends on regulatory approvals, market acceptance, and their ability to compete with larger pharmaceutical companies. The key to Nutriband's success will be commercializing its pipeline of abuse-deterrent patches. They need to look out for regulatory hurdles and competition from existing and new entrants to the market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is based on available information and is not financial advice. Warrant prices are highly volatile and can result in a complete loss. Market share data is an estimate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nutriband Inc. Warrant

Exchange NASDAQ
Headquaters Orlando, FL, United States
IPO Launch date 2021-10-01
Founder, CEO & Director Mr. Gareth Sheridan
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.